BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 25294512)

  • 1. [CDKN2A-mutation in a family with hereditary malignant melanoma].
    Djursby M; Wadt K; Lorentzen H; Borg A; Gerdes AM; Krogh L
    Ugeskr Laeger; 2014 Sep; 176(40):. PubMed ID: 25294512
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Uptake of genetic counseling, genetic testing and surveillance in hereditary malignant melanoma (CDKN2A) in Norway.
    Levin T; Mæhle L
    Fam Cancer; 2017 Apr; 16(2):257-265. PubMed ID: 27804060
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genetic counselling and high-penetrance susceptibility gene analysis reveal the novel CDKN2A p.D84V (c.251A>T) mutation in melanoma-prone families from Italy.
    Borroni RG; Manganoni AM; Grassi S; Grasso M; Diegoli M; Giorgianni C; Favalli V; Pavoni L; Cespa M; Arbustini E
    Melanoma Res; 2017 Apr; 27(2):97-103. PubMed ID: 28060055
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cancer risks and survival in patients with multiple primary melanomas: Association with family history of melanoma and germline CDKN2A mutation status.
    Helgadottir H; Tuominen R; Olsson H; Hansson J; Höiom V
    J Am Acad Dermatol; 2017 Nov; 77(5):893-901. PubMed ID: 28818438
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CDKN2A germline alterations in melanoma patients with personal or familial history of pancreatic cancer.
    De Unamuno B; García-Casado Z; Bañuls J; Requena C; Lopez-Guerrero JA; Nagore E
    Melanoma Res; 2018 Jun; 28(3):246-249. PubMed ID: 29543703
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CDKN2A germ-line mutations in individuals with multiple cutaneous melanomas.
    Hashemi J; Platz A; Ueno T; Stierner U; Ringborg U; Hansson J
    Cancer Res; 2000 Dec; 60(24):6864-7. PubMed ID: 11156381
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genetic susceptibility to cutaneous melanoma in southern Switzerland: role of CDKN2A, MC1R and MITF.
    Mangas C; Potrony M; Mainetti C; Bianchi E; Carrozza Merlani P; Mancarella Eberhardt A; Maspoli-Postizzi E; Marazza G; Marcollo-Pini A; Pelloni F; Sessa C; Simona B; Puig-Butillé JA; Badenas C; Puig S
    Br J Dermatol; 2016 Nov; 175(5):1030-1037. PubMed ID: 27473757
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phenotypic and Histopathological Tumor Characteristics According to CDKN2A Mutation Status among Affected Members of Melanoma Families.
    Taylor NJ; Handorf EA; Mitra N; Avril MF; Azizi E; Bergman W; Bianchi-Scarrà G; Bishop DT; Bressac-de Paillerets B; Calista D; Cannon-Albright LA; Cuellar F; Cust AE; Demenais F; Elder DE; Friedman E; Gerdes AM; Ghiorzo P; Goldstein AM; Grazziotin TC; Hansson J; Hayward NK; Hocevar M; Höiom V; Holland EA; Ingvar C; Landi MT; Landman G; Larre-Borges A; Leachman SA; Mann GJ; Nagore E; Olsson H; Palmer J; Perić B; Pjanova D; Puig S; Schmid H; van der Stoep N; Tucker MA; Wadt KAW; Whitaker L; Yang XR; Newton Bishop JA; Gruis NA; Kanetsky PA;
    J Invest Dermatol; 2016 May; 136(5):1066-1069. PubMed ID: 26827760
    [No Abstract]   [Full Text] [Related]  

  • 9. CDKN2A mutations with p14 loss predisposing to multiple nerve sheath tumours, melanoma, dysplastic naevi and internal malignancies: a case series and review of the literature.
    Sargen MR; Merrill SL; Chu EY; Nathanson KL
    Br J Dermatol; 2016 Oct; 175(4):785-9. PubMed ID: 26876133
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genetic test reporting of CDKN2A provides informational and motivational benefits for managing melanoma risk.
    Aspinwall LG; Stump TK; Taber JM; Drummond DM; Kohlmann W; Champine M; Leachman SA
    Transl Behav Med; 2018 Jan; 8(1):29-43. PubMed ID: 29385581
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CDKN2A/CDK4 Status in Greek Patients with Familial Melanoma and Association with Clinico-epidemiological Parameters.
    Karagianni F; Njauw CN; Kypreou KP; Stergiopoulou A; Plaka M; Polydorou D; Chasapi V; Pappas L; Stratigos IA; Champsas G; Panagiotou P; Gogas H; Evangelou E; Tsao H; Stratigos AJ; Stefanaki I
    Acta Derm Venereol; 2018 Oct; 98(9):862-866. PubMed ID: 29774366
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phenocopies in melanoma-prone families with germ-line CDKN2A mutations.
    Helgadottir H; Olsson H; Tucker MA; Yang XR; Höiom V; Goldstein AM
    Genet Med; 2018 Sep; 20(9):1087-1090. PubMed ID: 29215650
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Improvement of Genetic Testing for Cutaneous Melanoma in Countries With Low to Moderate Incidence: The Rule of 2 vs the Rule of 3.
    Delaunay J; Martin L; Bressac-de Paillerets B; Duru G; Ingster O; Thomas L
    JAMA Dermatol; 2017 Nov; 153(11):1122-1129. PubMed ID: 28903138
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CDKN2A and CDK4 mutation analysis in Italian melanoma-prone families: functional characterization of a novel CDKN2A germ line mutation.
    Della Torre G; Pasini B; Frigerio S; Donghi R; Rovini D; Delia D; Peters G; Huot TJ; Bianchi-Scarra G; Lantieri F; Rodolfo M; Parmiani G; Pierotti MA
    Br J Cancer; 2001 Sep; 85(6):836-44. PubMed ID: 11556834
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Germline CDKN2A Mutation Status and Survival in Familial Melanoma Cases.
    Helgadottir H; Höiom V; Tuominen R; Nielsen K; Jönsson G; Olsson H; Hansson J
    J Natl Cancer Inst; 2016 Nov; 108(11):. PubMed ID: 27287845
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CDKN2A germline mutations in individuals with cutaneous malignant melanoma.
    Orlow I; Begg CB; Cotignola J; Roy P; Hummer AJ; Clas BA; Mujumdar U; Canchola R; Armstrong BK; Kricker A; Marrett LD; Millikan RC; Gruber SB; Anton-Culver H; Zanetti R; Gallagher RP; Dwyer T; Rebbeck TR; Kanetsky PA; Wilcox H; Busam K; From L; Berwick M;
    J Invest Dermatol; 2007 May; 127(5):1234-43. PubMed ID: 17218939
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Analysis of Latvian familial melanoma patients shows novel variants in the noncoding regions of CDKN2A and that the CDK4 mutation R24H is a founder mutation.
    Veinalde R; Ozola A; Azarjana K; Molven A; Akslen LA; Doniņa S; Proboka G; Cēma I; Baginskis A; Pjanova D
    Melanoma Res; 2013 Jun; 23(3):221-6. PubMed ID: 23546221
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical germline genetic testing for melanoma.
    Hansen CB; Wadge LM; Lowstuter K; Boucher K; Leachman SA
    Lancet Oncol; 2004 May; 5(5):314-9. PubMed ID: 15120668
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Germline Variation at CDKN2A and Associations with Nevus Phenotypes among Members of Melanoma Families.
    Taylor NJ; Mitra N; Goldstein AM; Tucker MA; Avril MF; Azizi E; Bergman W; Bishop DT; Bressac-de Paillerets B; Bruno W; Calista D; Cannon-Albright LA; Cuellar F; Cust AE; Demenais F; Elder DE; Gerdes AM; Ghiorzo P; Grazziotin TC; Hansson J; Harland M; Hayward NK; Hocevar M; Höiom V; Ingvar C; Landi MT; Landman G; Larre-Borges A; Leachman SA; Mann GJ; Nagore E; Olsson H; Palmer JM; Perić B; Pjanova D; Pritchard A; Puig S; van der Stoep N; Wadt KAW; Whitaker L; Yang XR; Newton Bishop JA; Gruis NA; Kanetsky PA;
    J Invest Dermatol; 2017 Dec; 137(12):2606-2612. PubMed ID: 28830827
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Familial atypical multiple mole melanoma (FAMMM) syndrome: history, genetics, and heterogeneity.
    Lynch HT; Shaw TG
    Fam Cancer; 2016 Jul; 15(3):487-91. PubMed ID: 26892865
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.